HomeNewsBusinessStartupSwiggy to lay off 350 employees due to COVID-19 pandemic

Swiggy to lay off 350 employees due to COVID-19 pandemic

Swiggy in May had laid off 1,100 employees across grades and functions in cities and head office as part of its exercise to realign resources to create capacity in higher potential areas with the optimism of the business attaining pre-COVID levels in the near-term.

July 27, 2020 / 22:18 IST
Story continues below Advertisement
Swiggy | The online food aggregator raised $153 million in February 2020 from Samsung Ventures, Korea Investment Partners, Wellington Management, Naspers, Tencent and others. (Image Source: Swiggy)
Swiggy | The online food aggregator raised $153 million in February 2020 from Samsung Ventures, Korea Investment Partners, Wellington Management, Naspers, Tencent and others. (Image Source: Swiggy)

Food ordering and delivery platform Swiggy on Monday said it is laying off 350 employees as part of the realignment exercise it started in May on account of the impact of COVID-19 pandemic.

Swiggy in May had laid off 1,100 employees across grades and functions in cities and head office as part of its exercise to realign resources to create capacity in higher potential areas with the optimism of the business attaining pre-COVID levels in the near-term.

Story continues below Advertisement

"However, with the industry still only having recovered to about 50 percent of its peak, we have to, unfortunately, go ahead with this final realignment exercise, which will result in the net loss of 350 jobs," Swiggy said in a statement.

The company is concluding the exercise it began late May and there are no plans for any further restructuring, Swiggy said.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show